Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

ACTIVE NOT RECRUITING NA

Comparing an Operation to Monitoring, With or Without Endocrine Therapy (COMET) Trial For Low Risk DCIS

NCT02926911 · View on ClinicalTrials.gov ↗

Study Summary

This study looks at the risks and benefits of active monitoring (AM) compared to surgery in the setting of a pragmatic prospective randomized trial for low risk DCIS. Our overarching hypothesis is that management of low-risk Ductal Carcinoma in Situ (DCIS) using an AM approach does not yield inferior cancer or quality of life outcomes compared to surgery.

Interventions

  • OTHER Surgery
  • OTHER Active Monitoring

Study Locations (20)

Illinois

  • John H Stroger Jr Hospital of Cook County — Chicago
  • University of Chicago Medical Center — Chicago
  • Advocate Illinois Masonic Medical Center — Chicago
  • NorthShore University HealthSystem-Evanston Hospital — Evanston
  • Ingalls Memorial Hospital — Harvey
  • Illinois Cancer Care — Peoria

California

  • City of Hope — Duarte
  • Cedars-Sinai Medical Center — Los Angeles
  • Sharp Memorial Hospital — San Diego
  • Kaiser Permanente Medical Center — Vallejo

Colorado

  • Colorado Cancer Research Program — Denver
  • Saint Joseph Hospital- Cancer Centers of Colorado — Lafayette

Florida

  • Memorial Healthcare System — Hollywood
  • Mayo Clinic Florida — Jacksonville

Alaska

  • Providence Alaska Medical Center — Anchorage

Arizona

  • Mayo Clinic — Phoenix

Connecticut

  • Smilow Cancer Hospital at Yale-New Haven — New Haven

District of Columbia

  • MedStar Washington Hospital Center — Washington D.C.

Trial Details

FieldValue
Enrollment Target 997 participants
Start Date 2017-02-22
Est. Completion 2030-07
Phase NA

Sponsor

Alliance Foundation Trials

71 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02926911

The ClinicalTrials.gov registry entry for NCT02926911 describes a study currently listed as active not recruiting. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 997 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alliance Foundation Trials, which has 71 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 2 conditions, with Ductal Carcinoma in Situ appearing as the primary indexed condition, and to 2 interventions — of which Surgery is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT02926911 reports 20 study locations spanning 10 distinct geographic areas — top geographies include Illinois, California, Colorado. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT02926911 about?

NCT02926911 is a clinical study titled "Comparing an Operation to Monitoring, With or Without Endocrine Therapy (COMET) Trial For Low Risk DCIS". This study looks at the risks and benefits of active monitoring (AM) compared to surgery in the setting of a pragmatic prospective randomized trial for low risk DCIS. Our overarching hypothesis is that management of low-risk Ductal Carcinoma in Situ (DCIS) using an AM approach does not yield inferio...

What is the current status of trial NCT02926911?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 997 participants. The study started on 2017-02-22. Estimated completion is 2030-07.

What conditions does trial NCT02926911 study?

This clinical trial studies the following conditions: Ductal Carcinoma in Situ, DCIS. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT02926911?

The interventions under investigation include: Surgery (OTHER), Active Monitoring (OTHER). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT02926911?

This trial is sponsored by Alliance Foundation Trials, which has 71 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT02926911 being conducted?

This trial has 20 study locations across Alaska, Arizona, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial